ARCA biopharma, Inc.
NASDAQ:ABIO
Overview | Financials
Company Name | ARCA biopharma, Inc. |
Symbol | ABIO |
Currency | USD |
Price | 28.8 |
Market Cap | 34,817,184 |
Dividend Yield | 0% |
52-week-range | 2.247 - 53.88 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Michael R. Bristow M.D., Ph.D. |
Website | https://www.arcabio.com |
An error occurred while fetching data.
About ARCA biopharma, Inc.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD